WO2021170449A1 - Vitamin k2 synthesis - Google Patents

Vitamin k2 synthesis Download PDF

Info

Publication number
WO2021170449A1
WO2021170449A1 PCT/EP2021/053706 EP2021053706W WO2021170449A1 WO 2021170449 A1 WO2021170449 A1 WO 2021170449A1 EP 2021053706 W EP2021053706 W EP 2021053706W WO 2021170449 A1 WO2021170449 A1 WO 2021170449A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
vitamin
present
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2021/053706
Other languages
English (en)
French (fr)
Inventor
Werner Bonrath
Rolf Kuenzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to EP21704811.5A priority Critical patent/EP4110753A1/en
Priority to BR112022016774A priority patent/BR112022016774A2/pt
Priority to JP2022543714A priority patent/JP2023514491A/ja
Priority to CN202180016011.7A priority patent/CN115151524B/zh
Priority to US17/801,681 priority patent/US12139456B2/en
Publication of WO2021170449A1 publication Critical patent/WO2021170449A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C07C46/02—Preparation of quinones by oxidation giving rise to quinoid structures
    • C07C46/06—Preparation of quinones by oxidation giving rise to quinoid structures of at least one hydroxy group on a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/10—Quinones the quinoid structure being part of a condensed ring system containing two rings
    • C07C50/14—Quinones the quinoid structure being part of a condensed ring system containing two rings with unsaturation outside the ring system, e.g. vitamin K1

Definitions

  • the present invention relates to a new process of production of menaquinone 4, which is also known as Vitamin K2.
  • Vitamin K2 or menaquinone is one of three types of vitamin K, the other two being Vitamin K1 (phylloquinone) and K3 (menadione).
  • K2 is a bacterial product and is usually found in fermented foods or animal products, such as eggs, dairy, and meat, as well as fermented foods such as cheese and yogurt.
  • vitamin K2 There are nine chemical variants of vitamin K2, determined by number of isoprenyl units in their side chains.
  • MK-4 menaquinone 4
  • Menaquinone 4 (MK-4) has the following chemical formula
  • Vitamin K2 has very interesting and important properties.
  • vitamin K2 may lower the risk of cardiovascular damage and improve overall heart health.
  • Vitamin K2 promotes healthy bone mineral density by carboxylating osteocalcin, a protein that binds calcium to bones.
  • a 2016 study investigated the effects of vitamin K2 in rats with metabolic syndrome, high blood glucose levels and symptoms of anxiety, depression, and memory deficit.
  • Vitamin K2 has antioxidant properties that may help protect against cancer. In addition, findings suggest that K2 may suppress genetic processes that lead to tumor growth.
  • Vitamin K2 can be found in eggs, dairy, and meat, as well as fermented foods such as cheese and yogurt.
  • Vitamin K2 can be also be produced chemically. There are few ways known from the prior art how to produce vitamin K2. For example, from US 2007/0060761 or Kozlov, E. I., Med- itsinskaya Promyshlennost SSSR (1965), 19(4), 16-21).
  • the goal of the present invention was to find a new process to produce mena- quinone 4 (or an intermediate, which can then be used in the production of menaquinone 4).
  • the process according to the present invention relates to the production of the compound of formula (I), which is an intermediate in the menaquinone 4 production
  • the new process according to the present invention used the compound of formula (II) wherein as starting material.
  • 4-Hydroxy-2-methylnaphthalen-1-yl benzoate can be purchased commercially or it is easy to be produced (Ullmann's Encyclopedia of Industrial Chemistry, 1996, A27, 488 - 506).
  • the compound of formula (I) is used in a condensa tion reaction with geranyl geraniol, which is the compound of formula (III)
  • the new and improved process according to the present invention is carried out in the presence of a heterogeneous catalyst.
  • the heterogeneous catalyst used in the process according to the present invention is a triflate catalyst.
  • Preferred triflate catalysts are those of formula (IV) wherein M is Al, Bi or Sc.
  • the present invention relates to the process (P) for the production of the com pound of formula (I)
  • the present invention relates to the process (P’), which is process (P), wherein the heterogeneous catalyst is a compound of formula (IV) wherein M is Al, Bi or Sc.
  • the heterogeneous catalyst can be separated easily from the reaction mixture, Furthermore, the Al, Bi snd Sc catalyst of the present invention are more effective than Zn catalyst, which are used in the prior art. Furthermore far less of the catalysts of the present invention are needed when compared to the prior art.
  • the process according to the present invention is usually carried out in an inert solvent- systems.
  • the inert solvent system can be apolar as well as polar or a mixture of such solvents.
  • Suitable solvent systems are two-phase solvent systems with an apolar phase based on linear or branched C 6 - C12 aliphatic (such as 2-ethylhexane, heptane, decane or dodec- ane) and a polar phase based on ethylene carbonate or propylene carbonate (or a mixture of ethylene carbonate and propylene carbonate (usually 1:1 mixture)).
  • the present invention relates to the process (P1), which is process (P) or (P’), wherein the process is carried out in an inert solvent system.
  • the present invention relates to the process (PT), which is process (P1), wherein the solvent system is two-phase solvent system with an apolar phase based on linear or branched C 6 - C12 aliphates (such as 2-ethylhexane, heptane, decane or dodec- ane) and a polar phase based on ethylene carbonate or propylene carbonate (or a mixture of ethylene carbonate and propylene carbonate (usually 1:1 mixture)).
  • the solvent system is two-phase solvent system with an apolar phase based on linear or branched C 6 - C12 aliphates (such as 2-ethylhexane, heptane, decane or dodec- ane) and a polar phase based on ethylene carbonate or propylene carbonate (or a mixture of ethylene carbonate and propylene carbonate (usually 1:1 mixture)).
  • the present invention relates to the process (P1 ”), which is process (P1) or (PT), wherein the apolar solvent is chosen from the group consisting of 2-ethylhexane, heptane, decane and dodecane and the polar solvent is chosen from the group consisting of ethylene carbonate an propylene carbonate.
  • the process according to the present invention is usually carried out at elevated temper atures.
  • the process according to the present invention is carried out at a temperature of 30°C to 150°C, preferably 50°C - 120°C.
  • the present invention relates to the process (P2), which is process (P), (P’), (P1), (PT) or (P1 ”), wherein the process is carried out at elevated temperatures.
  • the present invention relates to the process (P2’), which is process (P), (P’), (P1), (PT) or (P1”) wherein the process is carried out at a temperature of 30°C to 150°C.
  • the present invention relates to the process (P2”), which is process (P), (P’), (P1), (PT) or (P1”) wherein the process is carried out at a temperature of 50°C - 120°C.
  • the process according to the present invention is usually carried out under ambient pres sure.
  • the present invention relates to the process (P3), which is process (P), (P’), (P1), (PT), (P1 ”), (P2), (P2’) or (P2”), wherein the process is carried out under ambient pressure.
  • the compound of formula (II) and the compound of formula (III) can be used in an equimolar amount. It is also possible that one of the starting materials (the compound of formula (II) and the compound of formula (III)) can be used in excess. In such a case, it is possible to use up to two times (mol equivalent) of one of the starting materials.
  • the molar ratio of the compound of formula (II) to the compound of formula (III) can be 1:2 to 2:1, preferably, 1 :1.5 to 1.5:1
  • the present invention relates to the process (P4), which is process (P), (P’), (P1), (P1’), (P1”), (P2), (P2’), (P2”) or (P3), wherein the compound of formula (II) and the compound of formula (III) are used an equimolar amount.
  • the present invention relates to the process (P4’), which is process (P), (P’), (P1), (PT), (P1”), (P2), (P2’), (P2”) or (P3), wherein the molar ratio of the compound of formula (II) to the compound of formula (III) is 1:2 to 2:1.
  • the present invention relates to the process (P4”), which is process (P), (P’), (P1), (PT), (P1”), (P2), (P2’), (P2”) or (P3), wherein the molar ratio of the compound of formula (II) to the compound of formula (III) is 1 :1.5 to 1.5:1.
  • the catalyst (compound of formula (IV)) according to the present invention is used in cat alytic amounts.
  • the substrate to catalyst ratio is from 2000:1 to 50000:1 , preferably 1500:1 to 30000:1. This ratio is based on the molar amount of the compound of formula (II) to the catalyst of formula (IV).
  • the present invention relates to the process (P5), which is process (P), (P’), (P1), (PT), (P1”), (P2), (P2’), (P2”), (P3), (P4), (P4’) or (P4”), wherein the substrate to catalyst ratio (based on the molar amount of the compound of formula (II) to the catalyst of formula (IV)) is from 2000:1 to 50000:1.
  • the present invention relates to the process (P5’), which is process (P5), wherein the substrate to catalyst ratio (based on the molar amount of the compound of formula (II) to the catalyst of formula (IV)) is from 1500:1 to 30000:1.
  • the process according to the present invention can be carried out under an inert gas atmosphere.
  • the inert can be any commonly used inert gas (or mixture thereof).
  • Suitable gases are N2 or argon.
  • the present invention relates to the process (P6), which is process (P), (P’), (P1), (P1’), (P1”), (P2), (P2’), (P2”), (P3), (P4), (P4’). (P4”), (P5) or (P5’), wherein the process is carried out under an inert gas atmosphere.
  • the present invention relates to the process (P6’), which is process (P6), wherein the inert gas is chosen from the group consisting of N2 or argon.
  • the obtained product of formula (I) can be isolated or reaction mixture (after the reaction has finished) to produce vitamin K2.
  • the compound of formula (I) is oxidized after saponification.
  • the saponification can be carried out with NaOH (aq) and the oxidation can be carried out with oxygen.
  • the organic phase is concentrated on a rotary evaporator at 40 °C to 17 mbar and de gassed for 30 minutes at high vacuum to ⁇ 0.1 mbar at 40 °C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/EP2021/053706 2020-02-25 2021-02-16 Vitamin k2 synthesis Ceased WO2021170449A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP21704811.5A EP4110753A1 (en) 2020-02-25 2021-02-16 Vitamin k2 synthesis
BR112022016774A BR112022016774A2 (pt) 2020-02-25 2021-02-16 Síntese de vitamina k2
JP2022543714A JP2023514491A (ja) 2020-02-25 2021-02-16 ビタミンｋ２の合成
CN202180016011.7A CN115151524B (zh) 2020-02-25 2021-02-16 维生素k2合成
US17/801,681 US12139456B2 (en) 2020-02-25 2021-02-16 Vitamin K2 synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159175.7 2020-02-25
EP20159175 2020-02-25

Publications (1)

Publication Number Publication Date
WO2021170449A1 true WO2021170449A1 (en) 2021-09-02

Family

ID=69740132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/053706 Ceased WO2021170449A1 (en) 2020-02-25 2021-02-16 Vitamin k2 synthesis

Country Status (6)

Country Link
US (1) US12139456B2 (https=)
EP (1) EP4110753A1 (https=)
JP (1) JP2023514491A (https=)
CN (1) CN115151524B (https=)
BR (1) BR112022016774A2 (https=)
WO (1) WO2021170449A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060761A1 (en) 2005-09-15 2007-03-15 Eisai Co., Ltd. Method for producing quinone compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768650A (en) * 1954-01-12 1957-02-20 Merck & Co Inc Vitamin k intermediates
DE3801743A1 (de) 1987-07-03 1989-01-19 Bayer Ag Schaedlingsbekaempfungsmittel auf basis von substituierten 1,4-naphthochinonen und neue substituierte 1,4-naphthochinone
US6790463B2 (en) 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
CN100344621C (zh) 2003-01-13 2007-10-24 帝斯曼知识产权资产管理有限公司 α－生育酚乙酸酯的生产方法
WO2005005407A1 (en) 2003-07-08 2005-01-20 Dsm Ip Assets B.V. Manufacture of tocopherols using a bismuth catalyst
WO2007032378A1 (ja) * 2005-09-15 2007-03-22 Eisai R & D Management Co., Ltd. キノン化合物の製造方法
WO2008099858A1 (ja) * 2007-02-13 2008-08-21 Kaneka Corporation 硬化性組成物
CN102351677B (zh) * 2011-09-16 2014-04-09 重庆大学 一种化学合成维生素k2的方法
JP6064264B2 (ja) 2011-12-27 2017-01-25 ディーエスエム アイピー アセッツ ビー．ブイ． ビタミンａ中間体の触媒合成
CN104513149A (zh) 2013-09-29 2015-04-15 天津瑞安医药科技发展有限公司 四烯甲萘醌的合成方法
CN104744230A (zh) 2015-02-13 2015-07-01 安徽万和制药有限公司 一种合成维生素k1的方法
CN105399615A (zh) 2015-10-23 2016-03-16 山东广通宝医药有限公司 一种合成维生素k1的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060761A1 (en) 2005-09-15 2007-03-15 Eisai Co., Ltd. Method for producing quinone compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Ullmann's Encyclopedia of Industrial Chemistry", vol. A27, 1996, pages: 488 - 506
KOZLOV, E. I., MED-ITSINSKAYA PROMYSHLENNOST SSSR, vol. 19, no. 4, 1965, pages 16 - 21
YOSHITOMO SUHARA ET AL: "Method for the Determination of Vitamin K Homologues in Human Plasma Using High-Performance Liquid Chromatography-Tandem Mass Spectrometry", ANALYTICAL CHEMISTRY, vol. 77, no. 3, 1 February 2005 (2005-02-01), pages 757 - 763, XP055441579, ISSN: 0003-2700, DOI: 10.1021/ac0489667 *

Also Published As

Publication number Publication date
US12139456B2 (en) 2024-11-12
CN115151524A (zh) 2022-10-04
US20230159429A1 (en) 2023-05-25
CN115151524B (zh) 2024-01-19
JP2023514491A (ja) 2023-04-06
BR112022016774A2 (pt) 2022-10-11
EP4110753A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
US4009122A (en) Novel glycol soluble molybdenum catalysts and method of preparation
CN114133350A (zh) 一种抗新冠药物Paxlovid中间体的制备方法
US9561500B2 (en) Catalyst composition and process for oligomerization of ethylene
RU2003127385A (ru) Способ получения эпоксида
US20040147714A1 (en) Process for the preparation of cyclic lactic acid oligomers
WO2021170449A1 (en) Vitamin k2 synthesis
TWI546283B (zh) （甲基）丙烯酸苯酯的製造方法及（甲基）丙烯酸苯酯組成物
CN101538191B (zh) 一种高纯度丙泊酚的合成方法
FR2482970A1 (fr) Procede de polymerisation d'une a-olefine
KR101126948B1 (ko) 비칼루타미드의 제조 방법 및 그 중간체의 정제 방법
US4266081A (en) Process for preparation of peroxides
EA045706B1 (ru) Синтез витамина k2
JPH01233291A (ja) アルキルアルシンの製造法
CN103025719B (zh) 制备二乙烯基芳烃二氧化物的方法
CN104725336A (zh) 一种在室温下制备1,2-柠檬烯环氧化物的方法
CN115385786B (zh) 一种维生素k2的合成方法
JPH06211821A (ja) オレフィン化合物のエポキシ化方法
JP4127017B2 (ja) ベンジルカルバゼート化合物の製造法
JPH0723332B2 (ja) １，３−ジクロル−２−プロパノ−ルの製造法
RU2726126C1 (ru) Способ получения 2-(8,9,17,18,22,23-гексаокса-20-азадиспиро[6.2.6.7]трикозан-20-ил)уксусных кислот
JPH024210B2 (https=)
JPH0656760A (ja) ２，５−ジクロロアルキルチオベンゼンの製造法
JP2891533B2 (ja) α―（４―イソブチルフェニル）エチルハイドロパーオキサイドおよびその製造方法
JP4752102B2 (ja) エポキシ化剤用有機ハイドロパーオキサイド組成物及びエポキシ化合物の製造方法
KR101940350B1 (ko) 2-클로로메틸벤즈알데히드의 제조 방법, 2-클로로메틸벤즈알데히드 함유 조성물 및 그 보관 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21704811

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022543714

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022016774

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021704811

Country of ref document: EP

Effective date: 20220926

ENP Entry into the national phase

Ref document number: 112022016774

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220823

WWG Wipo information: grant in national office

Ref document number: 202217040327

Country of ref document: IN